Vertex Pharmaceuticals (VRTX) Receivables - Net (2009 - 2026)

Vertex Pharmaceuticals' Receivables - Net history runs 18 years deep, the most recent figure standing at $2.0 billion for Q1 2026.

• In Q1 2026, Receivables - Net rose 10.58% year-over-year to $2.0 billion; the TTM figure through Mar 2026 stood at $2.0 billion (up 10.58% YoY), while the FY2025 annual figure was $2.1 billion, up 27.55% from the prior year.
• Receivables - Net for Q1 2026 stood at $2.0 billion, down from $2.1 billion in the prior quarter.
• The five-year high for Receivables - Net was $2.1 billion in Q4 2025, with the low at $1.3 billion in Q1 2022.
• The 5-year median for Receivables - Net is $1.6 billion (2024), against an average of $1.7 billion.
• The sharpest annual moves came in 2022 and 2025: Receivables - Net soared 43.45% in 2022, then gained 0.66% in 2025.
• Vertex Pharmaceuticals' Receivables - Net stood at $1.4 billion in 2022, then rose by 8.4% to $1.6 billion in 2023, then increased by 2.94% to $1.6 billion in 2024, then grew by 27.55% to $2.1 billion in 2025, then declined by 2.76% to $2.0 billion in 2026.
• Business Quant data shows VRTX's Receivables - Net at $2.0 billion in Q1 2026, $2.1 billion in Q4 2025, and $1.9 billion in Q3 2025.